马红球菌pRErm46质粒介导的多重耐药谱研究
本研究用15种抗菌药物筛查马红球菌临床分离株,发现pRErm46质粒除erm(46)外还通过1类整合子携带的sul1、aaA9及tetRA(33)决定簇增加对甲氧苄啶-磺胺甲噁唑、多西环素、链霉素等耐药,多数MDR株携带rpoB S531F突变。
要点
- 马红球菌(含MDR株)通常对利奈唑胺、米诺环素、替加环素、阿米卡星、妥布霉素敏感。
- pRErm46质粒通过1类整合子区sul1、aaA9及tetRA(33)增加磺胺、氨基糖苷和四环素类耐药。
- 约30%的erm(46)阳性株出现1类整合子区自发缺失,提示耐药谱可变。
核心结论
- pRErm46质粒除erm(46)外还通过1类整合子区sul1、aaA9及tetRA(33)决定簇 confer 对甲氧苄啶-磺胺甲噁唑、多西环素、链霉素、壮观霉素和四环素的耐药。
- 多数MDR马红球菌分离株携带2287克隆的rpoB S531F突变,但两例检出S531L和S531Y提示新MDR株出现。
研究设计与样本
- 用15种抗快速生长分枝杆菌和诺卡菌等需氧放线菌的抗菌药物 panel 筛查马红球菌临床分离株(含敏感株和MDR株)。
主要发现
- 按金黄色葡萄球菌判读标准,马红球菌(含MDR株)通常对利奈唑胺、米诺环素、替加环素、阿米卡星和妥布霉素敏感。
- 按CLSI RGM/NAA指南,马红球菌对亚胺培南、头孢西丁和头孢曲松敏感。
- 按EUCAST标准,对环丙沙星和莫西沙星的敏感性为临界。
- 分子分析显示pRErm46与clarithromycin外,RGM/NAA panel中甲氧苄啶-磺胺甲噁唑和多西环素MIC显著升高相关,并与链霉素、壮观霉素和四环素耐药相关。
- 约30%的erm(46)阳性分离株出现1类整合子区自发缺失的pRErm46变体,表明新耐药由sul1、aaA9及相邻tetRA(33)决定簇导致。
关键数值与推荐
- 利奈唑胺、米诺环素、替加环素、阿米卡星、妥布霉素按金黄色葡萄球菌判读标准判为敏感。
- 亚胺培南、头孢西丁、头孢曲松按CLSI RGM/NAA指南判为敏感。
- 环丙沙星和莫西沙星按EUCAST标准为临界。
临床怎么用
- 对马红球菌感染,可优先考虑利奈唑胺、米诺环素、替加环素、阿米卡星、妥布霉素及亚胺培南、头孢西丁、头孢曲松。
- 检测erm(46)阳性时应关注1类整合子区sul1、aaA9及tetRA(33)带来的额外耐药,避免仅依据大环内酯类耐药选药。
- 对MDR马红球菌应进行rpoB突变检测以识别2287克隆及潜在新MDR株。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal multidrug resistance recently emerged in Rhodococcus equi, complicating the therapeutic management of this difficult-to-treat animal- and human-pathogenic actinomycete. The currently spreading multidrug-resistant (MDR) "2287" clone arose in equine farms upon acquisition, and coselection by mass macrolide-rifampin therapy, of the pRErm46 plasmid carrying the erm(46) macrolide-lincosamide-streptogramin resistance determinant, and of an rpoBS531F mutation. Here, we screened a collection of susceptible and macrolide-resistant R. equi strains from equine clinical cases using a panel of 15 antimicrobials against rapidly growing mycobacteria (RGM) and nocardiae and other aerobic actinomycetes (NAA). R. equi isolates-including MDR ones-were generally susceptible to linezolid, minocycline, tigecycline, amikacin, and tobramycin according to Staphylococcus aureus interpretive criteria, plus imipenem, cefoxitin, and ceftriaxone based on Clinical and Laboratory Standards Institute (CLSI) guidelines for RGM/NAA. Susceptibility to ciprofloxacin and moxifloxacin was borderline according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. Molecular analyses linked pRErm46 to significantly increased MICs for trimethoprim-sulfamethoxazole and doxycycline, in addition to clarithromycin, within the RGM/NAA panel, and to streptomycin, spectinomycin, and tetracycline resistance. pRErm46 variants with spontaneous deletions in the class 1 integron (C1I) region, observed in ≈30% of erm(46)-positive isolates, indicated that the newly identified resistances were attributable to the C1I's sulfonamide (sul1) and aminoglycoside (aaA9) resistance cassettes and adjacent tetRA(33) determinant. Most MDR isolates carried the rpoBS531F mutation of the 2287 clone, while different rpoB mutations (S531L, S531Y) detected in two cases suggest the emergence of novel MDR R. equi strains.
引用
- Erol E, Scortti M, Fortner J, et al. Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi. J Clin Microbiol. 2021. PMID: 34319806. doi:10.1128/JCM.01149-21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。